Vol. 41 | Vol. 41(3) - May / June 2023 | COLUMN: API of the Month

Pirtobrutinib

by 31 May 2023

R. Souza 31 May 2023

Pirtobrutinib

RODRIGO SOUZA
Biocatalysis and Organic Synthesis Group, Chemistry Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazils

Pirtobrutinib (Jaypirca) is a non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor developed by Eli Lilly indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.

ABOUT THE AUTHOR

Rodrigo Souza – Since I started my independent career, I have pursuit the development of new technologies to guide research by innovative ideas. We have been working at Federal University of Rio de Janeiro on the establishment of continuous flow technology for active pharmaceutical ingredients (API) synthesis in Brazil, showing that is possible to reduce costs on production allowing the reduction of the final price of the medicine.

Regulatory toxicology: more experts needed

Latest issue

Vol. 44(4) – July / August 2026

View Issue

Content from magazine

“Contents from Magazine” offers curated articles and insights from the field of chemistry, focused on research, data, and scientific developments

View all content

Pirtobrutinib

You may also like

Peptides and Oligonucleotides, common trends as drugs

Procos’ HPAPI unit expansion & future investments

Kathy Ackley, Oligonucleotide CMC Consultant

Synthetic Chemistry in Nucleic Acid Drugs Recent progress in bridged n...

Oligonucleotides: Right Place, Right time, Right future

Regulatory toxicology: more experts needed